NCT06158841: Phase 3: Intravenous (IV) ABBV-383 Monotherapy Versus Standard Therapies Relapsed/Refractory Myeloma
NCT05572515: Phase 3: MajesTEC-9 - Teclistamab alone Versus Pomalidomide-Bort-Dex or Carfilzomib-dex
NCT05405166: Phase 3: SC Versus IV Isatuximab in Combination With Pomalidomide & Dexamethasone RRMM
NCT05455320: Phase 3 - (Talquetamab) Tal-DP Vs Tal-D Vs DPd - RRMM -Multiple Myeloma (MonumenTAL-3)
NCT05519085: Phase 3: CC-92480 + Bortezomib-dex (480Vd) Vs Pom-Bortzomib-dex (PVd) RRMM -SUCCESSOR-1
NCT05556616: Phase 1: A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma
NCT05288062: Phase 2: Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) + Dex
NCT05259839: Phase 1: IV Infused ABBV-383 With Anti-Cancer Regimens for Relapsed/Refractory Myeloma
NCT05050097: Phase 1 - A Study of Talquetamab With Other Anticancer Therapies in Multiple Myeloma
NCT05083169: Phase 3 - Tec-Dara Vs DPd Vs DVd in Relapsed or Refractory Myeloma - MajesTEC-3
NCT05028348: Phase 3: EMN 29 - Selinexor, Pom, Dex (SPd) Vs Elotuzumab, Pom, Dex in RRMM Myeloma
NCT05020236: Phase 3-MagnetisMM-5: Elranatamab (PF-06863135) Vs & Elranatamab/Dara VS Dara/Pom/Dex
NCT04855136 : Phase 1/2 - Safety and Efficacy of bb2121 (Ide-cel) Combinations in MM (KarMMa-7)
NCT04764942: Phase 1/2: Selinexor, Pom, Dex +/- Carfilzomib RRMM Multiple Myeloma, The SCOPE Trial
NCT04942067: Phase 1/2: APG-2575 in Combination With Novel Therapeutic Regimens in RRMM Myeloma
NCT04843579: Phase 2: Selinexor in Combination With Clarithromycin, Pom & Dex RRMM - ClaSPd
NCT04835129: Phase 2: Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in RRMM (IMPEDE)
NCT04722146: Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma
NCT04458831: A Non-interventional, Multinational, Observational study With Isatuximab in RRMM
NCT04508790: Phase 2: Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of RRMM Myeloma
NCT04287855: Phase 2: Phase 2 Study of Isatuximab + Pomalidomide, Dex, Carfilzomib RRMM -IFM2018-03
NCT04484623: Phase 3 - Belantamab Mafodotin & Pom/Dex (Pd) Vs Bortezomib & Pd in Ref. MM (DREAMM 8)
NCT04302324: Phase 2: Daratumumab, Clarithromycin, Pomalidomide And Dex RRMM - D-ClaPd
NCT03984097: Phase 1: A Study to Evaluate Subcutaneous TAK-079 Added to Standard Regimens NDMM
NCT04045795: Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
NCT04176718: Phase 2 - Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
NCT04068597: Phase 1/2: Study to Evaluate CCS1477 in Haematological Malignancies - RRMM Myeloma
NCT04150965: Phase 1/2: Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT
NCT04108195: Phase 1b - Subcutaneous Dara With Bispecific T Cell Redirection Antibodies - TRIMM-2
NCT04035226 - Study of Real-life Current Standards of Care in Patients With RRMM with 3 prior lines
NCT038282: Phase 1 - Dose Esc Study Belantamab mafodotin (GSK2857916) in Japanese With Refr MM
NCT04162210: Phase 3 - Belantamab Mafodotin Vs Pomalidomide + Low-dose Dexamethasone (Pom/Dex) RRMM
NCT04094961: Phase 1/2: Ixazomib + Pomalidomide + Dexamethasone In MM
NCT03590652: Phase 2 - Daratumumab, Ixazomib, Pomalidomide + Dex as Salvage Therapy Refractory MM
NCT03651128: Phase 3 - Study of bb2121 Vs Standard Regimens Refractory Myeloma (RRMM) (KarMMa-3)
NCT03715478: Phase 1/2: Multi-Center Study of GSK2857916 With Pomalidomide & Dex - Algonquin trial
NCT03539744: Phase 3 - A Study of Venetoclax/Dex Compared With Pomalidomide/Dex - t(11;14) +ive RRMM
NCT03756896: Phase 2: Carfilzomib, Pomalidomide, and Dexamethasone in High-Risk Myeloma
NCT03732703: Phase 1/2: Myeloma-Developing Regimens Using Genomics (MyDRUG)
NCT03180736 : Phase 3 - EMN 14 - Pomalidomide and Dexa +/- Dara in relapsed MM - APOLLO study
NCT03151811: Phase 3- Melphalan Flufenamide (Melflufen)-Dex or Pom-dex for RRMM ref. to Len. (OCEAN)
NCT03269136: Phase 1 -PF-06863135 As Single Agent & with Immunomodulatory Agents In relapsed Myeloma
NCT03215524: Phase 2 - Daratumumab, Low-Dose Dex and Cyclophosphamide +/- Pomalidomide (DCDP)
NCT03030261: Phase 2: Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second ASCT RRMM
NCT02990338: Phase 3 - Isatuximab, Pomalidomide & Dex VS Pom & Dex in relapsed Myeloma (ICARIA-MM)
NCT02654132 : Phase 2 Trial of Pomalidomide/Dexamethasone With or Without Elotuzumab ( ELOQUENT-3)
NCT02612779: Phase 2 - Elotuzumab in Combination With Pomalidomide and Low dose Dex Vs Nivo/Elo
NCT02119468: Phase 1/2: Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With RRMM